阿立哌唑对老年阿尔茨海默病合并精神障碍患者各精神症状量表评分影响

Effect of aripiprazole on the scores of psychiatric symptoms in elderly patients with Alzheimers disease complicated with mental disorders

ES评分 0

DOI
刊名
Journal of International Psychiatry
年,卷(期) 2019, 46(1)
作者
作者单位

南阳市中心医院神经内科 ;

摘要
【摘要】目的:研究阿立哌唑对老年阿尔茨海默病合并精神障碍患者各精神症状量表评分的影响。方法:研究对象选取我院2016年1月到2017年3月间收治的老年阿尔茨海默病合并精神障碍患者128例,采用随机数字法将其分为对照组和观察组,每组各64例。对照组患者接受奋乃静治疗,观察组患者接受阿立哌唑治疗。比较两组患者治疗前后阿尔茨海默病病理行为评定量表(BEHAV-AD)、社会功能评定量表(PSP)及治疗后副反应量表(TESS)评分。结果:治疗后2、4、6、8周,观察组患者的BEHAV-AD总评分均明显低于对照组(P<0.01),观察组在偏执和妄想、幻觉、攻击、活动异常、昼夜节律紊乱、情感障碍、焦虑和恐惧各方面BEHAV-AD评分均明显低于对照组(P<0.05)。治疗后2、4、6、8周,观察组患者PSP 总评分均显著高于对照组(P<0.01)。治疗后8周,观察组患者TESS评分为(6.88±1.36),明显低于对照组(8.78±2.13)(t=5.36,P=0.00)。结论:阿立哌唑能更好治疗患者阳性、阴性精神异常症状,提高患者生活质量和社交能力,且治疗安全性较高,椎体外系不良反应少,值得在临床推广。
Abstract
[Abstract] Objective: To study the effect of aripiprazole on the scores of psychiatric symptoms in elderly patients with Alzheimers disease complicated with mental disorders. Methods: 128 cases of elderly patients with Alzheimers disease complicated with mental disorders were selected from January 2016 to March 2017 in our hospital. They were randomly divided into control group and observation group, with 64 cases in each group. The control group received perphenazine treatment, and the observation group received aripiprazole treatment. The Behavioral Pathology in Alzheimers Disease Rating Scale (BEHAV-AD), the Personal and Social Performance Scale (PSP) and the Treatment Emergent Symptom Scale (TESS) score were compared between the two groups before and after treatment. Results: At 2, 4, 6, 8 weeks after treatment, the total scores of BEHAV-AD in the observation group were significantly lower than those in the control group (P<0.01), the scores of BEHAV-AD in the aspects of paranoia, delusion, hallucination, attack, abnormal activity, circadian rhythm disorder, emotional disorder, anxiety and fear in the observation group were lower than those in the control group (P<0.05). At 2, 4, 6, 8 weeks after treatment, the total score of PSP in the observation group was significantly higher than that in the control group(P<0.01). At 8 weeks after treatment, the score of TESS in the observation group was (6.88 + 1.36), which was significantly lower than that of the control group (8.78 + 2.13)(T=5.36,P=0.00).Conclusion: Aripiprazole can better treat patients with positive and negative mental abnormalities, improve the quality of life and social ability of patients, and the treatment of high safety, less adverse reaction of the vertebral body, it is worthy of clinical promotion
关键词
阿尔茨海默病;精神障碍;阿立哌唑;精神症状量表
KeyWord
Blzheimers disease; mental disorders; aripiprazole; psychiatric symptom scale
基金项目
页码 123-125
  • 参考文献
  • 相关文献
  • 引用本文

赵辉*. 阿立哌唑对老年阿尔茨海默病合并精神障碍患者各精神症状量表评分影响 [J]. 国际精神病学杂志. 2019; 46; (1). 123 - 125.

  • 文献评论

相关学者

相关机构